RESOLOR (prucalopride ) is a novel enterokinetic
treatment for chronic constipation in a patient population not adequately relieved by laxative treatments.
Effects of the enterokinetic
prucalopride (R093877) on colonic motility in fasted dogs.
Effect of different prokinetic agents and a novel enterokinetic
agent on postoperative ileus in rats.
Prucalopride is the first compound of a new class of highly selective serotonin (5-HT4) receptor agonists with strong enterokinetic
Prucalopride is the first compound of a new class of highly selective serotonin (5HT4) receptor agonists with strong enterokinetic
activity especially on the colon.
Prucalopride is a novel enterokinetic
treatment, and the first compound in a new generation of selective, high-affinity 5-HT4 receptor agonists, specifically designed to restore impaired bowel motility.
VIENNA, Austria, October 22 /PRNewswire/ -- New data presented at the United European Gastroenterology Week (UEGW) confirm the efficacy and safety of prucalopride, a novel enterokinetic
compound, in patients with chronic constipation for whom laxatives do not provide adequate relief.